QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) — QSAM Biosciences Inc. (OTCQB:QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”).
Related news for (QSAM)
- QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
- QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
- QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
- QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center